BioMarin Pharmaceutical Inc. (FRA:BM8)

Market Cap	9.14B -19.8%
Revenue (ttm)	2.64B +12.4%
Net Income	443.55M +61.5%
EPS	2.28 +59.5%
Shares Out	n/a
PE Ratio	20.61
Forward PE	12.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	55
Open	47.08
Previous Close	47.06
Day's Range	47.08 - 47.08
52-Week Range	43.86 - 68.96
Beta	n/a
RSI	45.95
Earnings Date	Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BM8

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD